Cardiometabolic Care: Assessing Patients with Diabetes Mellitus with No Overt Cardiovascular Disease in the Light of Heart Failure Development Risk

The mechanisms leading to the development of heart failure (HF) in diabetes mellitus (DM) patients are multifactorial. Assessing the risk of HF development in patients with DM is valuable not only for the identification of a high-risk subgroup, but also equally important for defining low-risk subpopulations. Nowadays, DM and HF have been recognized as sharing similar metabolic pathways. Moreover, the clinical manifestation of HF can be independent of LVEF classification. Consequently, approaching HF should be through structural, hemodynamic and functional evaluation. Thus, both imaging parameters and biomarkers are important tools for the recognition of diabetic patients at risk of HF manifestation and HF phenotypes, and arrhythmogenic risk, and eventually for prognosis, aiming to improve patients’ outcomes utilizing drugs and non-pharmaceutical cardioprotective tools such as diet modification.

[1]  D. Tousoulis,et al.  Diabetes Mellitus and Heart Failure: Epidemiology, Pathophysiologic Mechanisms, and the Role of SGLT2 Inhibitors , 2023, Life.

[2]  M. Yousefifard,et al.  Can metformin use reduce the risk of stroke in diabetic patients? A systematic review and meta-analysis. , 2023, Diabetes & metabolic syndrome.

[3]  M. Majdan,et al.  International evidence-based guidelines on hypertension and type 2 diabetes mellitus: A systematic review , 2023, Journal of public health research.

[4]  N. Tangri,et al.  Management of Type 2 Diabetic Kidney Disease in 2022: A Narrative Review for Specialists and Primary Care , 2023, Canadian journal of kidney health and disease.

[5]  D. Panagiotakos,et al.  Egg Consumption, Cardiovascular Disease and Cardiometabolic Risk Factors: The Interaction with Saturated Fatty Acids. Results from the ATTICA Cohort Study (2002–2012) , 2022, Nutrients.

[6]  Han Liu,et al.  The Molecular Mechanisms of Defective Copper Metabolism in Diabetic Cardiomyopathy , 2022, Oxidative medicine and cellular longevity.

[7]  M. Bai,et al.  NLRP3 Inflammasome/Pyroptosis: A Key Driving Force in Diabetic Cardiomyopathy , 2022, International journal of molecular sciences.

[8]  D. Burkhoff,et al.  HF?EF: The Mysterious Relationship Between Heart Failure and Ejection Fraction Continues. , 2022, Circulation.

[9]  C. Mantzoros,et al.  Quality of plant-based diets is associated with liver steatosis, which predicts type 2 diabetes incidence ten years later: Results from the ATTICA prospective epidemiological study. , 2022, Clinical Nutrition.

[10]  D. Panagiotakos,et al.  The association of specific types of vegetables consumption with 10-year type II diabetes risk: Findings from the ATTICA cohort study. , 2022, Journal of human nutrition and dietetics : the official journal of the British Dietetic Association.

[11]  A. Driscoll,et al.  Low Carbohydrate Diets for Diabetic Cardiomyopathy: A Hypothesis , 2022, Frontiers in Nutrition.

[12]  M. Obokata,et al.  Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality. , 2022, European heart journal.

[13]  M. Maiorino,et al.  Glycemic Control and the Heart: The Tale of Diabetic Cardiomyopathy Continues , 2022, Biomolecules.

[14]  C. Tschöpe,et al.  Epicardial Fat Expansion in Diabetic and Obese Patients With Heart Failure and Preserved Ejection Fraction—A Specific HFpEF Phenotype , 2021, Frontiers in Cardiovascular Medicine.

[15]  E. Nagel,et al.  Non-invasive CMR-Based Quantification of Myocardial Power and Efficiency Under Stress and Ischemic Conditions in Landrace Pigs , 2021, Frontiers in Cardiovascular Medicine.

[16]  Z. Zeng,et al.  Adherence to a Healthy Lifestyle and the Risk of All-Cause Mortality and Cardiovascular Events in Individuals With Diabetes: The ARIC Study , 2021, Frontiers in Nutrition.

[17]  G. Fonarow,et al.  Dietary interventions and nutritional supplements for heart failure: a systematic appraisal and evidence map , 2021, European journal of heart failure.

[18]  S. Schneeweiss,et al.  Comparative effectiveness and safety of sodium‐glucose cotransporter‐2 inhibitors versus metformin in patients with type 2 diabetes: An observational study using data from routine care , 2021, Diabetes, obesity & metabolism.

[19]  Sanjiv J. Shah,et al.  Visceral adiposity, muscle composition, and exercise tolerance in heart failure with preserved ejection fraction , 2021, ESC heart failure.

[20]  Zsolt Szekeres,et al.  The Effects of SGLT2 Inhibitors on Lipid Metabolism , 2021, Metabolites.

[21]  G. Fonarow,et al.  High‐protein vs. standard‐protein diets in overweight and obese patients with heart failure and diabetes mellitus: findings of the Pro‐HEART trial , 2021, ESC heart failure.

[22]  G. Sikand,et al.  Top 10 dietary strategies for atherosclerotic cardiovascular risk reduction , 2020, American journal of preventive cardiology.

[23]  Deepak L. Bhatt,et al.  Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. , 2020, The New England journal of medicine.

[24]  K. Howell,et al.  Modulation of the human gut microbiota by phenolics and phenolic fiber-rich foods. , 2020, Comprehensive reviews in food science and food safety.

[25]  L. Cugusi,et al.  Diabetic Cardiomyopathy and Ischemic Heart Disease: Prevention and Therapy by Exercise and Conditioning , 2020, International journal of molecular sciences.

[26]  G. Guyatt,et al.  Comparison of dietary macronutrient patterns of 14 popular named dietary programmes for weight and cardiovascular risk factor reduction in adults: systematic review and network meta-analysis of randomised trials , 2020, BMJ.

[27]  Davit Sargsyan,et al.  Gut Microbiota, Dietary Phytochemicals, and Benefits to Human Health , 2019, Current Pharmacology Reports.

[28]  T. Suvitaival,et al.  Targeted Clinical Metabolite Profiling Platform for the Stratification of Diabetic Patients , 2019, bioRxiv.

[29]  A. Kengne,et al.  Adiposity Mediates the Association between the Dietary Inflammatory Index and Markers of Type 2 Diabetes Risk in Middle-Aged Black South African Women , 2019, Nutrients.

[30]  N. Shivappa,et al.  Dietary inflammatory potential and risk of mortality in metabolically healthy and unhealthy phenotypes among overweight and obese adults. , 2019, Clinical nutrition.

[31]  Deepak L. Bhatt,et al.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019, The New England journal of medicine.

[32]  E. Abel,et al.  Heart Failure in Type 2 Diabetes Mellitus. , 2019, Circulation research.

[33]  M. Qorbani,et al.  Association of dietary inflammatory index with metabolic profile in metabolically healthy and unhealthy obese people , 2018, Nutrition & dietetics: the journal of the Dietitians Association of Australia.

[34]  D. Panagiotakos,et al.  Gender-specific, Lifestyle-related Factors and 10-year Cardiovascular Disease Risk; the ATTICA and GREECS Cohort Studies. , 2019, Current vascular pharmacology.

[35]  M. Pritzker,et al.  Impact of Exercise Training on Cardiac Function Among Patients With Type 2 Diabetes: A SYSTEMATIC REVIEW AND META-ANALYSIS , 2018, Journal of cardiopulmonary rehabilitation and prevention.

[36]  Mohammed K. Ali,et al.  Global Diabetes Prevention Interventions: A Systematic Review and Network Meta-analysis of the Real-World Impact on Incidence, Weight, and Glucose , 2018, Diabetes Care.

[37]  C. Cannon,et al.  Serial Measurement of Natriuretic Peptides and Cardiovascular Outcomes in Patients With Type 2 Diabetes in the EXAMINE Trial , 2018, Diabetes Care.

[38]  J. Sowers,et al.  Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity , 2018, Circulation research.

[39]  Thomas H Marwick,et al.  Assessment of Left Ventricular Function by Echocardiography: The Case for Routinely Adding Global Longitudinal Strain to Ejection Fraction. , 2018, JACC. Cardiovascular imaging.

[40]  J. Baldi,et al.  Exercise Training Improves but Does Not Normalize Left Ventricular Systolic and Diastolic Function in Adolescents With Type 1 Diabetes , 2017, Diabetes Care.

[41]  N. Benowitz,et al.  Cardiovascular effects of electronic cigarettes , 2017, Nature Reviews Cardiology.

[42]  Volkmar Falk,et al.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2016, Revista espanola de cardiologia.

[43]  G. Filippatos,et al.  Reframing the association and significance of co‐morbidities in heart failure , 2016, European journal of heart failure.

[44]  J. Rosenstock,et al.  Initial Combination Therapy With Canagliflozin Plus Metformin Versus Each Component as Monotherapy for Drug-Naïve Type 2 Diabetes , 2016, Diabetes Care.

[45]  F. Hu,et al.  Relation of Smoking With Total Mortality and Cardiovascular Events Among Patients With Diabetes Mellitus: A Meta-Analysis and Systematic Review , 2015, Circulation.

[46]  S. Turroni,et al.  High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome , 2015, Gut.

[47]  G. Hindricks,et al.  Association between ventricular arrhythmias and myocardial mechanical dispersion assessed by strain analysis in patients with nonischemic cardiomyopathy , 2015, Clinical Research in Cardiology.

[48]  C. Lam Diabetic cardiomyopathy: An expression of stage B heart failure with preserved ejection fraction , 2015, Diabetes & vascular disease research.

[49]  J. Mathers,et al.  Effects of the Dietary Approach to Stop Hypertension (DASH) diet on cardiovascular risk factors: a systematic review and meta-analysis. , 2015, The British journal of nutrition.

[50]  C. Tschöpe,et al.  New Insights in (Inter)Cellular Mechanisms by Heart Failure with Preserved Ejection Fraction , 2014, Current Heart Failure Reports.

[51]  M. Woodward,et al.  Do Cardiac Biomarkers NT-proBNP and hsTnT Predict Microvascular Events in Patients With Type 2 Diabetes? Results From the ADVANCE Trial , 2014, Diabetes Care.

[52]  M. Kontogianni,et al.  Mediterranean Diet and Diabetes: Prevention and Treatment , 2014, Nutrients.

[53]  E. Rimm,et al.  The Mediterranean-style dietary pattern and mortality among men and women with cardiovascular disease. , 2014, The American journal of clinical nutrition.

[54]  R. Prager,et al.  PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial. , 2013, Journal of the American College of Cardiology.

[55]  Deepak L. Bhatt,et al.  Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. , 2013, The New England journal of medicine.

[56]  A. Trichopoulou,et al.  Mediterranean diet and glycaemic load in relation to incidence of type 2 diabetes: results from the Greek cohort of the population-based European Prospective Investigation into Cancer and Nutrition (EPIC) , 2013, Diabetologia.

[57]  E. Kanoupakis,et al.  Sudden cardiac death in non-ischemic dilated cardiomyopathy: a critical appraisal of existing and potential risk stratification tools. , 2013, International journal of cardiology.

[58]  W. Paulus,et al.  A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. , 2013, Journal of the American College of Cardiology.

[59]  C. Watson,et al.  Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. , 2013, JAMA.

[60]  F. Guillén-Grima,et al.  The Mediterranean diet is associated with a reduction in premature mortality among middle-aged adults. , 2012, The Journal of nutrition.

[61]  T. Edvardsen,et al.  Risk assessment of ventricular arrhythmias in patients with nonischemic dilated cardiomyopathy by strain echocardiography. , 2012, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[62]  E. Oetjen Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: Evidence from a 37,229 patient meta-analysis , 2012 .

[63]  Ramachandran S Vasan,et al.  Diabetes and the risk of heart failure. , 2012, Heart failure clinics.

[64]  R. Prager,et al.  Repeat measurements of glycated haemoglobin A1c and N‐terminal pro‐B‐type natriuretic peptide: divergent behaviour in diabetes mellitus , 2011, European journal of clinical investigation.

[65]  G. Iacobellis,et al.  Epicardial adipose tissue: emerging physiological, pathophysiological and clinical features , 2011, Trends in Endocrinology & Metabolism.

[66]  J. McMurray,et al.  Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta-analysis. , 2011, American heart journal.

[67]  K. Bailey,et al.  The prognostic value of N-terminal pro-B-type natriuretic peptide for death and cardiovascular events in healthy normal and stage A/B heart failure subjects. , 2010, Journal of the American College of Cardiology.

[68]  P. Elliott,et al.  Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database , 2009, BMJ : British Medical Journal.

[69]  G. Nesbitt,et al.  Strain and Strain Rate Imaging in Cardiomyopathy , 2009, Echocardiography.

[70]  R. Prager,et al.  NT-proBNP has a high negative predictive value to rule-out short-term cardiovascular events in patients with diabetes mellitus. , 2008, European heart journal.

[71]  D. Chess,et al.  Role of diet and fuel overabundance in the development and progression of heart failure. , 2008, Cardiovascular research.

[72]  Craig J. Hartley,et al.  A novel feature-tracking echocardiographic method for the quantitation of regional myocardial function: validation in an animal model of ischemia-reperfusion. , 2008, Journal of the American College of Cardiology.

[73]  B. Zinman,et al.  Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. , 2006, The New England journal of medicine.

[74]  Qianwen Wang,et al.  Causes and characteristics of diabetic cardiomyopathy. , 2006, The review of diabetic studies : RDS.

[75]  H. Parving,et al.  Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes , 2006, Diabetologia.

[76]  Antoni Bayes-Genis,et al.  NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. , 2006, European heart journal.

[77]  D. Panagiotakos,et al.  Adherence to the Mediterranean diet is associated with total antioxidant capacity in healthy adults: the ATTICA study. , 2005, The American journal of clinical nutrition.

[78]  T. Borg,et al.  Structural and functional characterisation of cardiac fibroblasts. , 2005, Cardiovascular research.

[79]  W. Tang,et al.  Ischemic heart disease and congestive heart failure in diabetic patients. , 2004, The Medical clinics of North America.

[80]  P. Richardson Assessment of myocardial damage in dilated cardiomyopathy. , 1996, European heart journal.